This book describes histopathological assessment of preclinical toxicology studies that are conducted to assess the safety of novel drugs. It discusses the implications of drug-induced changes that may be relevant to the critical early stages of the development of new therapeutic agents, notably prior to their first administration to humans and during early clinical trials.
Covering virtually all aspects of drug-induced pathology in preclinical toxicity studies, the book is termed the 'gold standard' in the illustration of histopathology. This second revised edition continues to fill the gap for pathology literature relating to the development of new medicines and assessment of their safety based on preclinical studies. In addition to the updated references this edition contains many older references, some out of reach of modern computer based search tools
|